Jian Li

Jian Li is the SVP, Finance & Corporate Controller at DURECT. Jian has over 20 years of experience in the biotech industry, in both large and small companies.

Jian started their career at Takeda Oncology (Millennium Pharma) as a Scientist I, where they worked on therapeutic antibody and protein development. Jian then moved to Eisai US/Morphotech as a Group Lead, where they continued to work on developing therapeutic antibodies. In 2007, Jian was head of the Therapeutic Antibody Discovery and Development at Merck/Acceleron Pharma.

In 2010, Jian joined Pfizer as a Principal Scientist. At Pfizer, Jian worked on engineering therapeutic antibody/protein candidates (humanization and affinity maturation), optimization, and characterization. Jian left Pfizer in 2016 to join QLB Biotherapeutics as an Executive Director. At QLB Biotherapeutics, Jian was responsible for the discovery and development of antibody-based therapeutic candidates.

In 2020, Jian left QLB Biotherapeutics to join Dynamicure Biotechnology as a Vice President. At Dynamicure Biotechnology, Jian is responsible for the discovery and development of antibody-based biotherapeutics.

Jian Li attended the University of Pennsylvania for their Doctor of Philosophy in Molecular Biology and immunology. Jian then went on to Kyushu University for their M.D. in Huaxi Medical college.

Some of their coworkers include Judy Joice - SVP, Operations & Corporate Quality Assurance, Steve Helmer - Vice President, Chief Patent Counsel, and Andrew R. Miksztal - VP, Pharmaceutical Research & Development, Principal Scientist. Their manager is James E. Brown, President & CEO.